MedTrace Logo

Factor XIII Activity in Gastrointestinal Bleedings

NCT05933135 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2025-03-25

No results posted yet for this study

Summary

The aim of this retrospective study is to investigate the relationship between factor XIII activity and the outcome of gastrointestinal bleedings. Since factor XIII is of great importance in haemostasis and plays a key role in stabilizing the fibrin clot, it can be assumed that a deficiency of factor XIII leads to an unfavorable course of gastrointestinal bleedings. Our hypothesis is that early detection of such a deficiency can prevent a more severe course and that substitution of factor XIII contributes to faster cessation of bleeding, improves patient outcome and reduces the number of red cell concentrates required.

Conditions

  • Gastro Intestinal Bleeding

Interventions

DRUG

Factor XIII Injection

Patients could have had an Factor XIII Injection in clinical routine

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Christoph Hoegenauer, Prof. · Medical University of Graz

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-08
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05933135 on ClinicalTrials.gov